HomeCategoryCOVID-19 - Verséa

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/03/covid19_variant_409578937.jpeg?resize=1200%2C630&ssl=1

According to recent reports, the new BA.2 COVID-19 variant (a subvariant of the omicron variant called BA.1.) spreads more easily than the original omicron. Early data suggest that BA.2 is about 30% more transmissible than the original variant. The new BA.2 variant can also manifest different symptoms than the original strains. New symptoms include: Dizziness Fatigue...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/02/omicron_colourbox.jpg?resize=1200%2C640&ssl=1

Yesterday the WHO’s Technical Advisory Group on SARS-Cov-2 Virus Evolution (ATG-VE) published a statement on new omicron variants that have been circulating globally, accounting for nearly all sequences reported to GISAID: “Based on available data of transmission, severity, reinfection, diagnostics, therapeutics and impacts of vaccines, the group reinforced that the BA.2 sublineage should continue to...

https://i0.wp.com/www.versea.com/wp-content/uploads/2021/03/an-aerial-shot-of-people-standing-together-to-form-the-outline-of-the-novel-coronavirus-m.jpg?resize=800%2C400&ssl=1

Researchers screen rapid-detection COVID-19 tests for sensitivity/specificity, limit of detection, and time to results ANN ARBOR, MI, and VANCOUVER, BC—February 10, 2021—After screening more than 1,100 independently assessed, point-of-care COVID-19 tests, researchers at NSF International and Novateur Ventures have identified five direct (antigen/RNA) tests for detection of acute infection and six indirect (antibody) tests for...